On September 21, 2015 Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, treported that a late-breaker abstract was selected for an oral presentation at the 2015 European Cancer Congress (ECC) in Vienna, Austria (Press release, Ignyta, SEP 21, 2015, View Source [SID:1234507504]). The oral presentation relates to updated results of Phase 1 clinical trials of entrectinib, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumors that harbor activating alterations to NTRK1, NTRK2, NTRK3, ROS1 or ALK, and will be held on Sunday, September 27, 2015.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are honored that the ECC 2015 Scientific Program Committee has selected our late breaker abstract for an oral presentation session," said Pratik Multani, M.D., Chief Medical Officer of Ignyta. "We are looking forward to sharing updated data from our two Phase 1 clinical trials of entrectinib in this prestigious forum, and to discussing our entrectinib data and plans with key scientific and clinical experts."

Details of the presentation are as follows:

Date/time: Sunday, September 27, 2015, 5:20 PM, Vienna time
Title: Entrectinib (RXDX-101), an oral pan-Trk, ROS1, and ALK inhibitor in patients
with advanced solid tumors harboring gene rearrangements. (Abstract
number 29LBA)
Presenter: Salvatore Siena, M.D., Director, Niguarda Hospital Cancer Center, Milan, Italy